WallStreetZenWallStreetZen

NASDAQ: NDRA
Endra Life Sciences Inc Stock

Open Broker Account
$0.18+0.01 (+5.88%)
Updated Dec 8, 2022
NDRA Price
$0.18
Fair Value Price
$0.30
Market Cap
$11.31M
52 Week Low
$0.16
52 Week High
$0.91
P/E
-0.69x
P/B
1.11x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.99M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$12M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NDRA Overview

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Zen Score

Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NDRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NDRA ($0.18) is undervalued by 39.57% relative to our estimate of its Fair Value price of $0.30 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NDRA ($0.18) is significantly undervalued by 39.57% relative to our estimate of its Fair Value price of $0.30 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NDRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NDRA due diligence checks available for Premium users.

Be the first to know about important NDRA news, forecast changes, insider trades & much more!

NDRA News

Valuation

NDRA fair value

Fair Value of NDRA stock based on Discounted Cash Flow (DCF)
Price
$0.18
Fair Value
$0.30
Undervalued by
39.23%
NDRA ($0.18) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NDRA ($0.18) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NDRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NDRA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.69x
Industry
37.24x
Market
21.39x

NDRA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.11x
Industry
4.43x
NDRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NDRA's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.4M
Profit Margin
0%
NDRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$12.3M
Liabilities
$2.1M
Debt to equity
0.21
NDRA's short-term assets ($11.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NDRA's short-term assets ($11.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NDRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NDRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.2M
Investing
-$14.9k
Financing
$0.0
NDRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NDRA vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
NDRA$11.31M+6.55%-0.69x1.11x
LHDX$11.45M-7.54%-0.08x0.19x
BIOC$11.51M0.00%-0.68x0.42x
TTOO$10.98M+2.04%-0.09x-0.35x
CEMI$10.87M-1.00%-0.24x0.61x

Endra Life Sciences Stock FAQ

What is Endra Life Sciences's quote symbol?

NASDAQ: NDRA) Endra Life Sciences trades on the NASDAQ under the ticker symbol NDRA. Endra Life Sciences stock quotes can also be displayed as NASDAQ: NDRA.

If you're new to stock investing, here's how to buy Endra Life Sciences stock.

What is the 52 week high and low for Endra Life Sciences (NASDAQ: NDRA)?

(NASDAQ: NDRA) Endra Life Sciences's 52-week high was $0.91, and its 52-week low was $0.16. It is currently -80.33% from its 52-week high and 11.18% from its 52-week low.

How much is Endra Life Sciences stock worth today?

(NASDAQ: NDRA) Endra Life Sciences currently has 63,174,455 outstanding shares. With Endra Life Sciences stock trading at $0.18 per share, the total value of Endra Life Sciences stock (market capitalization) is $11.31M.

Endra Life Sciences stock was originally listed at a price of $3.90 in Jun 30, 2017. If you had invested in Endra Life Sciences stock at $3.90, your return over the last 5 years would have been -95.41%, for an annualized return of -46% (not including any dividends or dividend reinvestments).

How much is Endra Life Sciences's stock price per share?

(NASDAQ: NDRA) Endra Life Sciences stock price per share is $0.18 today (as of Dec 8, 2022).

What is Endra Life Sciences's Market Cap?

(NASDAQ: NDRA) Endra Life Sciences's market cap is $11.31M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Endra Life Sciences's market cap is calculated by multiplying NDRA's current stock price of $0.18 by NDRA's total outstanding shares of 63,174,455.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.